Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies

被引：4

作者：

Gressens, Simon B. ^{[1
]}

Wiedemann, Aurelie ^{[2
,4
]}

Dechenaud, Marie ^{[2
]}

Dupuis, Jehan ^{[3
]}

Gallien, Sebastien ^{[1
,4
]}

Melica, Giovanna ^{[1
,4
]}

Haioun, Corinne ^{[3
,4
]}

Lemonnier, Francois ^{[3
,4
]}

Levy, Yves ^{[1
,2
]}

机构：

[1] Univ Paris Est Creteil, Hop Univ Henri Mondor, AP HP, Infect Dis & Immunol Dept, Creteil, France

[2] Univ Paris Est Creteil, Vaccine Res Inst, Fac Med, Team 16,INSERM U955, Creteil, France

[3] Grp Hosp Univ Chenevier Mondor, Serv Unite Hemopathies Lymphoides, IAP HP, F-94010 Creteil, France

[4] Univ Paris Est Creteil, INSERM, IMRB, F-94010 Creteil, France

来源：

VACCINE | 2023年 / 41卷 / 09期

关键词：

Third dose; COVID-19; Immunocompromised; Vaccine; T cell responses; Hematological malignancies; SARS-COV-2; IMMUNITY;

D O I：

10.1016/j.vaccine.2023.01.064

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Patients receiving anti-CD20 antibodies showed limited efficacy of a booster dose of BNT162b2. Patients with lymphomas combine such immunotherapies with cytotoxic chemotherapies that could result in an even greater alteration of the immune response to vaccination. We report here the impact of a third vac-cine dose on T cell specific responses in a small cohort of patients treated in our center by anti-CD20 ther-apies and cytotoxic chemotherapies for lymphoid malignancies. Our results showed that a third dose in these severely immune suppressed patients could improve the expansion on CD4+Th1+T cell responses while the effect CD8 + T cell responses was marginal. (c) 2023 Elsevier Ltd. All rights reserved.

引用

页码：1550 / 1553

页数：4

共 50 条

[31] Comparative longitudinal variation of total IgG and IgA anti-SARS-CoV-2 antibodies in recipients of BNT162b2 vaccination
Lippi, Giuseppe
Salvagno, Gian Luca
Henry, Brandon M.
Pighi, Laura
De Nitto, Simone
Gianfilippi, Gianluca
ADVANCES IN LABORATORY MEDICINE-AVANCES EN MEDICINA DE LABORATORIO, 2022, 3 (01): : 39 - 43
[32] Effect of BNT162b2 booster dose on anti-SARS-CoV-2 spike trimeric IgG antibodies in seronegative individuals
Salvagno, Gian Luca
Henry, Brandon M.
Pighi, Laura
De Nitto, Simone
Gianfilippi, Gianluca
Lippi, Giuseppe
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2022, 60 (06) : 930 - 933
[33] Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study
Lasagna, A.
Bergami, F.
Lilleri, D.
Percivalle, E.
Quaccini, M.
Alessio, N.
Comolli, G.
Sarasini, A.
Sammartino, J. C.
Ferrari, A.
Arena, F.
Secondino, S.
Cicognini, D.
Schiavo, R.
Lo Cascio, G.
Cavanna, L.
Baldanti, F.
Pedrazzoli, P.
Cassaniti, I
ESMO OPEN, 2022, 7 (02)
[34] NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals
Cuapio, Angelica
Boulouis, Caroline
Filipovic, Iva
Wullimann, David
Kammann, Tobias
Parrot, Tiphaine
Chen, Puran
Akber, Mira
Gao, Yu
Hammer, Quirin
Strunz, Benedikt
Potti, Andre Perez
Ballesteros, Olga Rivera
Lange, Joshua
Muvva, Jagadeeswara Rao
Bergman, Peter
Blennow, Ola
Hansson, Lotta
Mielke, Stephan
Nowak, Piotr
Soderdahl, Gunnar
Osterborg, Anders
Smith, C. I. Edvard
Bogdanovic, Gordana
Muschiol, Sandra
Hellgren, Fredrika
Lore, Karin
Sobkowiak, Michal J.
Gabarrini, Giorgio
Healy, Katie
Chen, Margaret Sallberg
Alici, Evren
Bjorkstrom, Niklas K.
Buggert, Marcus
Ljungman, Per
Sandberg, Johan K.
Aleman, Soo
Ljunggren, Hans-Gustaf
MOLECULAR MEDICINE, 2022, 28 (01)
[35] Cerebral Venous Thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine
Dias, Leonor
Soares-Dos-Reis, Ricardo
Meira, Joao
Ferrao, Diana
Soares, Pedro Ribeirinho
Pastor, Ana
Gama, Guilherme
Fonseca, Luisa
Fagundes, Vitor
Carvalho, Marta
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2021, 30 (08)
[36] Effect of the third dose of BNT162b2 COVID-19 mRNA vaccine on anti-SARS-CoV-2 antibody levels in healthcare workers
Tanaka, Hidenori
Mukai, Junji
Kushibiki, Kenichi
Mizushima, Sayuri
Maeda, Kyoko
Fujimoto, Yuko
Sawada, Ryugo
Oda, Manabu
Okuda, Hiroshi
Yamaki, Mayumi
Hashiguchi, Shin
Kawai, Ichiro
Kawaguchi, Izumi
Masuda, Noriyuki
Matsushita, Haruhiko
VACCINE, 2023, 41 (02) : 365 - 371
[37] NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals
Angelica Cuapio
Caroline Boulouis
Iva Filipovic
David Wullimann
Tobias Kammann
Tiphaine Parrot
Puran Chen
Mira Akber
Yu Gao
Quirin Hammer
Benedikt Strunz
André Pérez Potti
Olga Rivera Ballesteros
Joshua Lange
Jagadeeswara Rao Muvva
Peter Bergman
Ola Blennow
Lotta Hansson
Stephan Mielke
Piotr Nowak
Gunnar Söderdahl
Anders Österborg
C. I. Edvard Smith
Gordana Bogdanovic
Sandra Muschiol
Fredrika Hellgren
Karin Loré
Michal J. Sobkowiak
Giorgio Gabarrini
Katie Healy
Margaret Sällberg Chen
Evren Alici
Niklas K. Björkström
Marcus Buggert
Per Ljungman
Johan K. Sandberg
Soo Aleman
Hans-Gustaf Ljunggren
Molecular Medicine, 2022, 28
[38] Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis
Chiara Pellicano
Roberta Campagna
Alessandra Oliva
Giorgia Leodori
Marzia Miglionico
Amalia Colalillo
Ivano Mezzaroma
Claudio Maria Mastroianni
Ombretta Turriziani
Edoardo Rosato
Clinical Rheumatology, 2022, 41 : 2755 - 2763
[39] Waning of Anti-SARS-CoV-2 Spike Antibody Levels 100 to 200 Days after the Second Dose of the BNT162b2 Vaccine
Matsunaga, Hidenori
Takeuchi, Hidefumi
Oba, Yuichiro
Fujimi, Satoshi
Honda, Tomoyuki
Tomonaga, Keizo
VACCINES, 2022, 10 (02)
[40] Humoral and cellular immune response to mRNA SARS-CoV-2 BNT162b2 vaccine in adolescents with rheumatic diseases
Clara Udaondo
Carmen Cámara
Laura Miguel Berenguel
Rosa Alcobendas Rueda
Celia Muñoz Gómez
Claudia Millán Longo
Blanca Díaz – Delgado
Iker Falces-Romero
Mariana Díaz Almirón
Jordi Ochando
Ana Méndez – Echevarría
Agustín Remesal Camba
Cristina Calvo
Pediatric Rheumatology, 20

← 1 2 3 4 5 →